ImmunoPrecise Antibodies opened its new 3,200 square foot state of the art antibody production laboratory at Vancouver Island Technology Park that has been designed in conjunction with Low Hammond Rowe Architects. The addition of this new laboratory:
- More than doubles the company’s lab footprint
- Allows for 3X the capacity for hybridoma projects
- Architectural and engineering features that enhance workflow and cleanliness
- Houses new equipment [High-throughput FACS] to expand services
- Allows for Vivarium expansion up to 10X the capacity for hybridoma projects
Tom D’Orazio, CEO of ImmunoPrecise, stated, “The opening of new laboratory facilities provides the infrastructure for the implementation of our strategic growth initiatives of increasing capacity and expansion of our core business. Perhaps more importantly for our shareholders, since increasing sales is tied to our capacity, the additional capacity of this world class facility allows us to handle more projects which we expect to drive revenues.”
“We have experienced steady growth in our hybridoma business driven by our Rapid Prime service for developing monoclonal antibodies,” said Teri Otto, Director of Laboratory Services for ImmunoPrecise. “The new lab gives us the space to support this growth for the foreseeable future. It also gives us the ability to improve efficiency, acquire additional equipment and better allow us to offer additional services such as humanizing antibodies.”
(Source: ImmunoPrecise Antibodies)
Follow us on Twitter and Facebook for updates on the latest pharmaceutical and biopharmaceutical manufacturing news!
